protein-name,gene-symbol,uniprot-id,rs-id,allele,defining-change,description,pubmed-id,parent_key
Low affinity immunoglobulin gamma Fc region receptor II-a,FCGR2A,P12318,rs1801274,,H allelle,Patients with this genotype may have increased progression-free survival time when using cetuximab to treat colorectal cancer.,17704420,DB00002
Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,P08637,rs396991,,G > T,Patients with this genotype have increased progression-free survival time when using cetuximab to treat colorectal cancer.,17704420,DB00002
Interferon lambda-3,IFNL3,Q8IZI9,rs12979860,,C > T,Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peginterferon alfa-2a therapy.,24096968,DB00008
Interferon lambda-3,IFNL3,Q8IZI9,rs12979860,,C > T,Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peginterferon alfa-2b therapy.,24096968,DB00022
Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,P08637,rs1801274,,CC Allele (homozygous),Patients with this genotype have increased ACR20 response when using infliximab to treat rheumatoid arthritis.,18930989,DB00065
Low affinity immunoglobulin gamma Fc region receptor III-A,FCGR3A,P08637,rs396991,FCGR3A,T > G,"Patients with this genotype have increased frequency of anti-tumor response when using rituximab to treat diffuse large B-cell lymphoma, follicular lymphoma, or [follicular non-Hodgkin lymphoma].",16609067,DB00073
Kinesin-like protein KIF6,KIF6,Q6ZMV9,rs20455,,C Allele,Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose pravastatin.,18222353,DB00175
3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,P04035,rs17244841,,T Allele,Patients with this genotype have a lesser reduction in LDL cholesterol with pravastatin.,15199031,DB00175
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.,25974703,DB00176
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.,25974703,DB00176
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.,25974703,DB00176
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.,25974703,DB00176
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.,,DB00176
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of fluvoxamine.,,DB00176
Angiotensin-converting enzyme,ACE,P12821,rs4344,,"A Allele, homozygote",Patients with this genotype have a shorter time to lowering of blood pressure with ramipril,17885551,DB00178
Angiotensin-converting enzyme,ACE,P12821,rs1799752,,Alu insertions,Patients with this genotype have increased frequency of positive erectile response when using sildenafil to treat erectile dysfunction,12837457,DB00203
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,"T allele, homozygote",Patients with this genotype have increased frequency of positive erectile response when using sildenafil to treat erectile dysfunction,12576843,DB00203
Multidrug resistance protein 1,ABCB1,P08183,rs2032583,,C Allele,Patients with this genotype have an increased likelihood of remission when using citalopram to treat major depressive disorder,17913323,DB00215
5-hydroxytryptamine receptor 2A,HTR2A,P28223,rs7997012,,A Allele,Patients with this genotype have an increased likelihood of responding to citalopram when treating major depressive disorder,16642436,DB00215
"Glutamate receptor ionotropic, kainate 4",GRIK4,Q16099,rs1954787,,C Allele,Patients with this genotype have an increased likelihood of responding to citalopram when treating major depressive disorder,17671280,DB00215
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,T Allele,Patients with this genotype have an increased likelihood of responding to elitriptan when treating (condition: cluster headache).,17361120,DB00216
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,Patients with this genotype have reduced metabolism of phenytoin.,15805193,DB00252
Beta-1 adrenergic receptor,ADRB1,P08588,rs1801252,,A Allele,Patients with this genotype have a greater reduction in blood pressure with metoprolol.,12844134,DB00264
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,Patients with this genotype have reduced metabolism of metoprolol.,18784654,DB00264
Beta-1 adrenergic receptor,ADRB1,P08588,rs1801253,,G > C,Patients with this genotype have a greater reduction in blood pressure with metoprolol.,12844134,DB00264
Cytochrome P450 1A2,CYP1A2,P05177,,-2964(G/A),A Allele,Patients with this genotype have reduced metabolism of theophylline.,12732846,DB00277
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A Allele,Patients with this genotype have reduced metabolism of venlafaxine.,16958828,DB00285
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,T deletion,Patients with this genotype have reduced metabolism of venlafaxine.,16958828,DB00285
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,"Whole gene deletion, homozygote",Patients with this genotype have reduced metabolism of venlafaxine.,16958828,DB00285
Multidrug resistance protein 1,ABCB1,P08183,rs2032583,,C Allele,Patients with this genotype have an increased likelihood of remission when using venlafaxine to treat major depressive disorder,17913323,DB00285
Multidrug resistance protein 1,ABCB1,P08183,rs2032583,,T > C,Patients with this genotype have increased risk of adverse events with venlafaxine,22641028,DB00285
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.,25919121,DB00289
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,"A Allele, homozygote",The presence of this genotype in CYP2D6 is associated with poor metabolism of atomoxetine and more frequent occurrence of adverse events.,25919121,DB00289
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole Gene Deletion,The presence of this genotype in CYP2D6 is associated with poor metabolism of atomoxetine and more frequent occurrence of adverse events.,25919121,DB00289
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,"T deletion, homozygote",The presence of this genotype in CYP2D6 is associated with poor metabolism of atomoxetine and more frequent occurrence of adverse events.,25919121,DB00289
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.,,DB00289
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this genotype in CYP2D6 may be associated with reduced metabolism of atomoxetine and more frequent occurrence of adverse events.,,DB00289
Bleomycin hydrolase,BLMH,Q13867,rs10500565,,G Allele,Patients with this genotype have reduced survival time and increased frequency of early relapse when using bleomycin to treat testicular cancer.,18398146,DB00290
Multidrug resistance protein 1,ABCB1,P08183,rs1045642,,T Allele,Patients with this genotype may have an increased analgesic response to morphine.,17898703,DB00295
Mu-type opioid receptor,OPRM1,P35372,rs1799971,,A Allele,Patients with this genotype may have an increased analgesic response to morphine.,17898703,DB00295
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,T Allele,Patients with this genotype have an increased likelihood of responding to zolmitriptan when treating (condition: cluster headache).,17361120,DB00315
Epidermal growth factor receptor,EGFR,P00533,rs121434568,L858R,T > G,The presence of this polymorphism in EGFR is associated with a higher response rate to gefitinib.,15118073,DB00317
Epidermal growth factor receptor,EGFR,P00533,rs28929495,G719A/C,G > A or C or T,The presence of this polymorphism in EGFR is associated with a higher response rate to gefitinib.,15118073,DB00317
Epidermal growth factor receptor,EGFR,P00533,rs121913444,L861Q,T > A or G,The presence of this polymorphism in EGFR is associated with a higher response rate to gefitinib.,15118073,DB00317
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,"A Allele, homozygote",Patients with this genotype have reduced metabolism of codeine.,1782973,DB00318
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,"T deletion, homozygote",Patients with this genotype have reduced metabolism of codeine.,1782973,DB00318
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,"Whole gene deletion, homozygote",Patients with this genotype have reduced metabolism of codeine.,1782973,DB00318
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 results in non-functioning enzyme variant and may be associated with reduced drug mtabolism or reduced therapeutic response when treated with codeine.,24458010,DB00318
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of codeine.,24458010,DB00318
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of codeine and lack of therapeutic response from codeine.,24458010,DB00318
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of codeine.,24458010,DB00318
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 results in non-functioning enzyme variant and may be associated with reduced therapeutic response when treated with codeine.,,DB00318
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 results in non-functioning enzyme variant and may be associated with reduced therapeutic response when treated with codeine.,,DB00318
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A Allele,Patients with this genotype have reduced metabolism of amitriptyline.,18070221,DB00321
Multidrug resistance protein 1,ABCB1,P08183,rs2032583,,C Allele,Patients with this genotype have an increased likelihood of remission when using amitriptyline to treat major depressive disorder,17913323,DB00321
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,G > A,Patients with this genotype have reduced metabolism of amitriptyline.,20531370,DB00321
Multidrug resistance protein 1,ABCB1,P08183,rs2032583,,T > C,Patients with this genotype have increased risk of adverse events with amitriptyline,22641028,DB00321
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.,27997040,DB00321
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.,27997040,DB00321
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.,27997040,DB00321
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.,27997040,DB00321
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,The presence of this polymorphism in CYP2C19 is associated with poor metabolism of amitriptyline.,27997040,DB00321
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of amitriptyline.,27997040,DB00321
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.,,DB00321
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of amitriptyline.,,DB00321
5-hydroxytryptamine receptor 1A,HTR1A,P08908,rs6295,,CC Allele (homozygous),The presence of this polymorphism in HTR1A may indicate a higher level of efficacy in improving negative symptoms of schizophrenia when treated with olanzapine.,20533011,DB00334
Beta-1 adrenergic receptor,ADRB1,P08588,rs1801253,,G > C,Patients with this genotype have a greater reduction in blood pressure with atenolol.,22192668,DB00335
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,"A Allele, homozygote",Patients with this genotype have reduced metabolism of omeprazole.,9867757,DB00338
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,"A Allele, homozygote",Patients with this genotype have reduced metabolism of omeprazole.,9867757,DB00338
Beta-1 adrenergic receptor,ADRB1,P08588,rs1801253,,C > G,Patients with this genotype require a lower dosage of diltiazem to achieve a favourable rate-control response when treating atrial fibrillation.,22192668,DB00343
Natriuretic peptides A,NPPA,P01160,rs5065,,AA allele,Patients with this genotype have increased risk of adverse cardiovascular outcomes with diuretics.,18212314,DB00381
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,"A Allele, homozygote",Patients with this genotype have reduced metabolism of lansoprazole.,9867757,DB00448
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,"A Allele, homozygote",Patients with this genotype have reduced metabolism of lansoprazole.,9867757,DB00448
Multidrug resistance protein 1,ABCB1,P08183,rs1045642,,"C Allele,  heterozygote",Patients with this genotype have increased plasma concentration of lansoprazole.,17190370,DB00448
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A Allele,Patients with this genotype have reduced metabolism of imipramine.,18070221,DB00458
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.,27997040,DB00458
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.,27997040,DB00458
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.,27997040,DB00458
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.,27997040,DB00458
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,The presence of this polymorphism in CYP2C19 is associated with poor metabolism of imipramine.,27997040,DB00458
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of imipramine.,27997040,DB00458
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.,,DB00458
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.,,DB00458
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,Patients with this genotype have reduced metabolism of celecoxib.,12893985,DB00482
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,"A Allele, homozygote",Patients with this genotype have reduced metabolism of dextromethorphan.,10513455,DB00514
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,"T deletion, homozygote",Patients with this genotype have reduced metabolism of dextromethorphan.,10513455,DB00514
Epidermal growth factor receptor,EGFR,P00533,rs28929495,G719A/C,G > A or C or T,The presence of this polymorphism in EGFR is associated with a higher response rate to erlotinib.,15118073,DB00530
Epidermal growth factor receptor,EGFR,P00533,rs121913444,L861Q,T > A or G,The presence of this polymorphism in EGFR is associated with a higher response rate to erlotinib.,15118073,DB00530
Epidermal growth factor receptor,EGFR,P00533,rs121434568,L858R,T > G,The presence of this polymorphism in EGFR is associated with a higher response rate to erlotinib.,15118073,DB00530
Cytochrome P450 3A4,CYP3A4,P08684,rs2740574,CYP3A4*1B,G Allelle,Patients with this genotype have reduced metabolism of cyclophosphamide to its active form and reduced disease free survival time when using cyclophosphamide to treat node-positive breast cancer.,20459744,DB00531
Cytochrome P450 2B6,CYP2B6,P20813,rs4802101,CYP2B6*1G,C Allelle,Patients with this genotype have reduced metabolism of cyclophosphamide to its active form.,17502835,DB00531
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,"A Allele, homozygote",Patients with this genotype have reduced metabolism of mephenytoin.,7969038,DB00532
Cytochrome P450 2C19,CYP2C19,P33261,rs41291556,CYP2C19*8,T > C,Patients with this genotype have reduced metabolism of mephenytoin.,10411572,DB00532
Cytochrome P450 2C19,CYP2C19,P33261,rs72558186,CYP2C19*7,T > A,Patients with this genotype have reduced metabolism of mephenytoin.,10411572,DB00532
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A Allele,Patients with this genotype have reduced metabolism of nortriptyline.,18070221,DB00540
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.,27997040,DB00540
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.,27997040,DB00540
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.,27997040,DB00540
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.,27997040,DB00540
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.,,DB00540
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of nortriptyline.,,DB00540
Sodium channel protein type 1 subunit alpha,SCN1A,P35498,rs3812718,,IVS5N + 5 G>A,Patients with this genotype have increased resistance to the anti-epileptic effects of carbamazepine.,24052718,DB00564
Cytochrome P450 2C19,CYP2C19,P33261,rs12248560,CYPC19*17,C > T,Patients with this genotype in CYP2C19 are ultra fast metabolizers and require higer doses of voriconazole to attain the therapeutic effect.,27981572,DB00582
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,The presence of this polymorphism in CYP2C19 is associated with poor metabolism of voriconazole.,27981572,DB00582
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of voriconazole.,27981572,DB00582
Cytochrome P450 2B6,CYP2B6,P20813,rs3745274,CYP2B6*6,G > T,The presence of this polymorphism in CYP2B6 is associated with reduction in efavirenz metabolism.,,DB00625
Kinesin-like protein KIF6,KIF6,Q6ZMV9,rs20455,,C Allele,Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose simvastatin.,18222353,DB00641
3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,P04035,rs17244841,,T Allele,Patients with this genotype have a lesser reduction in LDL cholesterol with simvastatin.,15199031,DB00641
Beta-1 adrenergic receptor,ADRB1,P08588,rs1801253,,G > C,Patients with this genotype require a lower dosage of verapamil to achieve a favourable rate-control response when treating atrial fibrillation.,22192668,DB00661
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,T Allele,Patients with this genotype have an increased likelihood of responding to sumatriptan when treating (condition: cluster headache).,17361120,DB00669
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,"A Allele, homozygote",Patients with this genotype have reduced metabolism of tamoxifen resulting in reduced plasma concentrations its active form endoxifen.,17115111,DB00675
Cytochrome P450 2C9,CYP2C9,P11712,rs1799853,CYP2C9*2,T Allele,Patients with this genotype have reduced metabolism of warfarin.,15608560,DB00682
Vitamin K epoxide reductase complex subunit 1,VKORC1,Q9BQB6,rs9923231,,-1639G>A,Patients with this genotype in VKORC1 are associated with reduced metabolism of warfarin and increased risk of serious bleeding thus require lower doses.,28198005,DB00682
Phylloquinone omega-hydroxylase CYP4F2,CP4F2,P78329,rs2108622,,"T Allele, homozygous",Patients with this genotype in CP4F2 may require higer doses of warfarin to attain therapeutic anticoagulant activity.,28198005,DB00682
Cytochrome P450 2C9,CYP2C9,P11712,rs1799853,CYP2C9*2,T Allele,The presence of this polymorphism in CYP2C9 is associated with reduction in warfarin metabolism.,28198005,DB00682
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,The presence of this polymorphism in CYP2C9 is associated with reduction in warfarin metabolism.,28198005,DB00682
Mu-type opioid receptor,OPRM1,P35372,rs1799971,,A > G,Patients with this genotype have an increased number of abstinent days when using naltrexone to treat alcohol addiction.,18250251,DB00704
Multidrug resistance protein 1,ABCB1,P08183,rs2032583,,C Allele,Patients with this genotype have an increased likelihood of remission when using paroxetine to treat major depressive disorder.,17913323,DB00715
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.,25974703,DB00715
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.,25974703,DB00715
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.,25974703,DB00715
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.,25974703,DB00715
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.,,DB00715
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.,,DB00715
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.,27997040,DB00726
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.,27997040,DB00726
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.,27997040,DB00726
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.,27997040,DB00726
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,The presence of this polymorphism in CYP2C19 is associated with poor metabolism of trimipramine.,27997040,DB00726
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of trimipramine.,27997040,DB00726
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.,,DB00726
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 is associated with poor metabolism of trimipramine.,,DB00726
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,"A Allele, homozygote",Patients with this genotype have reduced metabolism of esomeprazole.,9867757,DB00736
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,"A Allele, homozygote",Patients with this genotype have reduced metabolism of esomeprazole.,9867757,DB00736
Catechol O-methyltransferase,COMT,P21964,rs4680,,AA allele,Patients with this genotype have reduced improvement in vigor and well-being with modafinil.,19037200,DB00745
Catechol O-methyltransferase,COMT,P21964,rs4680,,GG allele,Patients with this genotype have increased improvement in vigor and well-being with modafinil.,19037200,DB00745
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,Patients with this genotype have reduced metabolism of clopidogrel resulting in reduced plasma concentrations of its active metabolite.,17900275,DB00758
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,G > A,Patients with this genotype have reduced metabolism of clopidogrel resulting in reduced plasma concentrations of its active metabolite.,8195181,DB00758
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of clopidogrel.,23698643,DB00758
Solute carrier organic anion transporter family member 1B1,SLCO1B1,Q9Y6L6,rs4149056,SLCO1B1*15,C Allele,Patients with this genotype have reduced transport of the active metabolite of irinotecan resulting in increased plasma concentrations.,17898662,DB00762
Interferon lambda-3,IFNL3,Q8IZI9,rs12979860,,C > T,Patients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to ribavirin therapy.,24096968,DB00811
Cytochrome P450 2D6,CYP2D6,P10635,rs1080985,CYP2D6*2A,C > G,Patients with this genotype are have a decreased likelihood of responding to donepezil when treating Alzheimer's disease.,22465999,DB00843
Cytochrome P450 3A5,CYP3A5,P20815,,CYP3A5*1,Functional gene,Patients with this genotype in CYP3A5 are extensive metabolizers and require higer doses of tacrolimus to attain the therapeutic effect.,25801146,DB00864
Cytochrome P450 2D6,CYP2D6,P10635,,"CYP2D6*1xN,",Gene duplication.,Patients with this genotype in CYP2D6 are ultrarapid metabolizers with an increased risk of poor therapeutic response and vomiting when treated with ondansteron.,28002639,DB00904
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*2xN,Gene duplication.,Patients with this genotype in CYP2D6 are ultrarapid metabolizers with an increased risk of poor therapeutic response and vomiting when treated with ondansteron.,28002639,DB00904
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,T Allele,Patients with this genotype have an increased likelihood of responding to almotriptan when treating cluster headache.,17361120,DB00918
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,Patients with this genotype have reduced metabolism of acetylsalicylic acid.,12893985,DB00945
Integrin beta-3,ITGB3,P05106,rs5918,GPIIIa PlA2,T > C,Patients with this genotype have increased resistance to the anti-thrombotic effects of aspirin.,11723016,DB00945
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,T Allele,Patients with this genotype have an increased likelihood of responding to naratriptan when treating (condition: cluster headache).,17361120,DB00952
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,T Allele,Patients with this genotype have an increased likelihood of responding to rizatriptan when treating (condition: cluster headache).,17361120,DB00953
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,T Allele,Patients with this genotype have an increased likelihood of responding to frovatriptan when treating (condition: cluster headache).,17361120,DB00998
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,Patients with this genotype have reduced metabolism of glipizide.,10208645,DB01067
Kinesin-like protein KIF6,KIF6,Q6ZMV9,rs20455,,C Allele,Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose atorvastatin.,18222353,DB01076
3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,P04035,rs17244841,,T Allele,Patients with this genotype have a lesser reduction in LDL cholesterol with atorvastatin.,15199031,DB01076
Cytochrome P450 3A4,CYP3A4,P08684,rs2740574,CYP3A4*1B,A > G,Patients with this genotype have an greater reduction in LDL cholesterol with atorvastatin.,22120734,DB01076
Kinesin-like protein KIF6,KIF6,Q6ZMV9,rs20455,,C Allele,Patients with this genotype have a greater reduction in risk of a major cardiovascular event with high dose rosuvastatin.,18222353,DB01098
3-hydroxy-3-methylglutaryl-coenzyme A reductase,HMGCR,P04035,rs17244841,,T Allele,Patients with this genotype have a lesser reduction in LDL cholesterol with rosuvastatin.,15199031,DB01098
ATP-binding cassette sub-family G member 2,ABCG2,Q9UNQ0,rs2231142,,G > T,Patients with this genotype have a greater reduction in LDL cholesterol with rosuvastatin.,20130569,DB01098
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,The presence of this polymorphism in CYP2C19 is associated with poor metabolism of sertraline.,25974703,DB01104
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of sertraline.,25974703,DB01104
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3,GNB3,P16520,rs5443,,C > T,Patients with this genotype will lose weight with sibutramine.,19687782,DB01105
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,The presence of this polymorphism in CYP2C19 is associated with reduction in gliclazide metabolism.,17298483,DB01120
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduction in gliclazide metabolism.,17298483,DB01120
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,Patients with this genotype have reduced metabolism of tolbutamide.,8873220,DB01124
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,"A Allele, homozygote",Patients with this genotype have reduced metabolism of proguanil.,13680037,DB01131
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,"A Allele, homozygote",Patients with this genotype have reduced metabolism of proguanil.,13680037,DB01131
Beta-1 adrenergic receptor,ADRB1,P08588,rs1801253,,"C Allele, homozygous",Patients with this genotype in ADRB1 have an increased likelihood of responding to carvedilol for the treatment of increased blood pressure.,12844134,DB01136
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.,27997040,DB01142
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.,27997040,DB01142
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.,27997040,DB01142
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.,27997040,DB01142
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,The presence of this polymorphism in CYP2C19 is associated with poor metabolism of doxepin.,27997040,DB01142
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of doxepin.,27997040,DB01142
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.,,DB01142
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.,,DB01142
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A Allele,Patients with this genotype have reduced metabolism of desipramine.,18070221,DB01151
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.,27997040,DB01151
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.,27997040,DB01151
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.,27997040,DB01151
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.,27997040,DB01151
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.,,DB01151
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.,,DB01151
D(2) dopamine receptor,DRD2,P14416,rs1800497,,"C Allele, homozygous",The presence of this genotype in DRD2 is associated with improved therapeutic response to bupropion.,18058343,DB01156
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,The presence of this polymorphism in CYP2C19 is associated with poor metabolism of escitalopram.,25974703,DB01175
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of escitalopram.,25974703,DB01175
T-box transcription factor TBX21,TBX21,Q9UL17,rs2240017,,CG allele (heterozygotes),The presence of this polymorphism in TBX21 may be associated with improved responsiveness to budenoside for the treatment of asthma.,15604153,DB01222
Potassium voltage-gated channel subfamily H member 2,KCNH2,Q12809,rs1805123,,A > C,The presence of this polymorphism in KCNH2 may be associated with increased clinical efficacy with metoclopramide.,22688145,DB01233
Alpha-1D adrenergic receptor,ADRA1D,P25100,rs2236554,,A > T,The presence of this polymorphism in ADRA1D may be associated with increased clinical efficacy with metoclopramide.,22688145,DB01233
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,G > A,Patients with this genotype have reduced metabolism of metoclopramide.,22688145,DB01233
Multidrug resistance protein 1,ABCB1,P08183,rs1045642,,T Allele,Patients with this polymorphism in ABCB1 may have a reduced response to clomipramine.,21840870,DB01233
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A Allele,Patients with this genotype have reduced metabolism of clomipramine.,18070221,DB01242
Cytochrome P450 2D6,CYP2D6,P10635,rs35742686,CYP2D6*3,2549delA,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.,27997040,DB01242
Cytochrome P450 2D6,CYP2D6,P10635,rs3892097,CYP2D6*4,A allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.,27997040,DB01242
Cytochrome P450 2D6,CYP2D6,P10635,,CYP2D6*5,Whole-gene deletion,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.,27997040,DB01242
Cytochrome P450 2D6,CYP2D6,P10635,rs5030655,CYP2D6*6,1707delT,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.,27997040,DB01242
Cytochrome P450 2C19,CYP2C19,P33261,rs4244285,CYP2C19*2,681G>A,The presence of this polymorphism in CYP2C19 is associated with poor metabolism of clomipramine.,27997040,DB01242
Cytochrome P450 2C19,CYP2C19,P33261,rs4986893,CYP2C19*3,636G>A,The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of clomipramine.,27997040,DB01242
Cytochrome P450 2D6,CYP2D6,P10635,rs1135824,CYP2D6*3,G allele,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.,,DB01242
Cytochrome P450 2D6,CYP2D6,P10635,rs28371733,CYP2D6*4,3877G>A,The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of clomipramine.,,DB01242
Cytochrome P450 2C9,CYP2C9,P11712,rs1799853,CYP2C9*2,T Allele,The presence of this polymorphism in CYP2C9 is associated with reduction in acenocoumarol metabolism.,18021343,DB01418
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,The presence of this polymorphism in CYP2C9 is associated with reduction in acenocoumarol metabolism.,18021343,DB01418
Cytochrome P450 2C9,CYP2C9,P11712,rs1799853,CYP2C9*2,T Allele,Patients with this polymorphism in CYP2C9 may be at a higher risk of developing drug-related hemorrhage or thrombosis when treated with acenocoumarol.,28033245,DB01418
Cytochrome P450 2C9,CYP2C9,P11712,rs1057910,CYP2C9*3,C Allele,Patients with this polymorphism in CYP2C9 may be at a higher risk of developing drug-related hemorrhage or thrombosis when treated with acenocoumarol.,28033245,DB01418
Cystic fibrosis transmembrane conductance regulator,CFTR,P13569,rs75527207,,"A allele (G > A), double homozygote",Patients who carry this polymorphism in CFTR will respond to ivacaftor therapy.,23757359,DB08820
Epidermal growth factor receptor,EGFR,P00533,rs121913444,L861Q,T > A or G,The presence of this polymorphism in EGFR is associated with a higher response rate to afatinib.,15118073,DB08916
Epidermal growth factor receptor,EGFR,P00533,rs121434568,L858R,T > G,The presence of this polymorphism in EGFR is associated with a higher response rate to afatinib.,15118073,DB08916
Epidermal growth factor receptor,EGFR,P00533,rs28929495,G719A/C,G > A or C or T,The presence of this polymorphism in EGFR is associated with a higher response rate to afatinib.,15118073,DB08916
5-hydroxytryptamine receptor 1A,HTR1A,P08908,rs6295,,CC Allele (homozygous),The presence of this polymorphism in HTR1A may indicate a higher level of efficacy in improving negative symptoms of schizophrenia when treated with perospirone.,20533011,DB08922
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs8175347,UGT1A1*28 or UGT1A 7/7,extra TA in promoter,Poor drug metabolizer.,24329186,DB08930
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs4148323,UGT1A1*6,G > A,The presence of this polymorphism in UGT1A1 is associated with reduction in dolutegravir metabolism.,24329186,DB08930
UDP-glucuronosyltransferase 1-1,UGT1A1,P22309,rs8175347,UGT1A1*37,TA pair insertion,The presence of this polymorphism in UGT1A1 is associated with reduction in dolutegravir metabolism.,24329186,DB08930
